MRD-guided Tislelizumab After Adjuvant Chemotherapy in Resected Non-Small Cell Lung Cancer (NSCLC)

• Status: Not yet recruiting
• Trial end date: 2026-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a single-center, single-arm phaseⅡtrial to explore a follow-up intervention mode after curative treatment for resected stage II/III NSCLC. MRD monitoring for recurrence in order to give earlier intervention to reduce the recurrence rate and improve the survival rate, and to evaluate the efficacy and safety of tislelizumab after adjuvant chemotherapy in resected NSCLC

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Song Zhao
• Collaborator: BeiGene

Criteria

Inclusion Criteria:

1. Patient with age ≥ 18 years old, gender is not limited.

2. Histologically confirmed primary NSCLC, postoperative stage is IIA, IIB, IIIA or T3N2IIIB.

3. Receiving surgery-based comprehensive treatment, that is, radical surgical resection combined with neoadjuvant chemotherapy or/and adjuvant chemotherapy recommended by the Chinese Medical Association's Lung Cancer Clinical Diagnosis and Treatment Guidelines.

4. Paraffin-embedded sections (10-15 pieces) or fresh frozen tissue are required.

5. ECOG score of 0 or 1.

6. Females of childbearing age should take appropriate contraceptive measures from screening to 3 months after discontinuation of study treatment and should not breastfeed. The pregnancy test was negative before starting dosing.

7. Male patients should use barrier contraception from screening to 3 months after discontinuation of study treatment.

8. The subjects themselves participated voluntarily and signed the informed consent in writing.

Exclusion Criteria:

1. The patient has received immune checkpoint inhibitors such as anti-PD-1, PD-L1 or CTLA-4, other immunotherapy or systemic immune modulators (including but not limited to interferon, IL-2 and TNF etc).

2. Histopathology with small cell or large cell endocrine tumor component.

3. Harboring EGFR sensitizing mutation or ALK gene translocation

4. History of other malignant tumors, except for non-melanoma skin cancer, carcinoma in situ or other solid tumors that have been effectively treated, and no evidence of any disease for >5 years after the last treatment.

5. At the start of the study treatment, there are residual toxicities of the previous treatment that are greater than CTCAE 1 and have not been alleviated, except for alopecia and grade 2 neurotoxicity caused by previous chemotherapy.

6. Any serious or uncontrolled systemic disease, including uncontrolled high blood pressure, active bleeding, active infection including hepatitis B, C, HIV, etc., which the investigator considers unsuitable to participate in the study or affect the trial program compliance.

7. History of ILD, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid therapy, or any evidence of clinically active interstitial lung disease

8. Insufficient bone marrow reserve or organ function.

9. History of hypersensitivity reactions to any active or inactive ingredient of tislelizumab or to drugs that are chemically similar to tislelizumab or in the same class of tislelizumab.

10. Patients who, in the judgment of the investigator, may not comply with the procedures and requirements of the study.

11. Patients who, in the investigator's judgment, have any condition that compromises patient safety or interferes with the evaluation of the study.